122 related articles for article (PubMed ID: 33230745)
21. Machine learning defined diagnostic criteria for differentiating pituitary metastasis from autoimmune hypophysitis in patients undergoing immune checkpoint blockade therapy.
Mekki A; Dercle L; Lichtenstein P; Nasser G; Marabelle A; Champiat S; Chouzenoux E; Balleyguier C; Ammari S
Eur J Cancer; 2019 Sep; 119():44-56. PubMed ID: 31415986
[TBL] [Abstract][Full Text] [Related]
22. Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context.
Wiesweg M; Mairinger F; Reis H; Goetz M; Kollmeier J; Misch D; Stephan-Falkenau S; Mairinger T; Walter RFH; Hager T; Metzenmacher M; Eberhardt WEE; Zaun G; Köster J; Stuschke M; Aigner C; Darwiche K; Schmid KW; Rahmann S; Schuler M
Eur J Cancer; 2020 Nov; 140():76-85. PubMed ID: 33059196
[TBL] [Abstract][Full Text] [Related]
23. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
25. Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer Patients.
Tahmassebi A; Wengert GJ; Helbich TH; Bago-Horvath Z; Alaei S; Bartsch R; Dubsky P; Baltzer P; Clauser P; Kapetas P; Morris EA; Meyer-Baese A; Pinker K
Invest Radiol; 2019 Feb; 54(2):110-117. PubMed ID: 30358693
[TBL] [Abstract][Full Text] [Related]
26. Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy.
Umemoto Y; Okano S; Matsumoto Y; Nakagawara H; Matono R; Yoshiya S; Yamashita Y; Yoshizumi T; Ikegami T; Soejima Y; Harada M; Aishima S; Oda Y; Shirabe K; Maehara Y
J Gastroenterol; 2015 Jan; 50(1):65-75. PubMed ID: 24509608
[TBL] [Abstract][Full Text] [Related]
27. Circulating PD-L1 is associated with T cell infiltration and predicts prognosis in patients with CRLM following hepatic resection.
Chen X; Du Z; Huang M; Wang D; Fong WP; Liang J; Fan L; Wang Y; Yang H; Chen Z; Hu M; Xu R; Li Y
Cancer Immunol Immunother; 2022 Mar; 71(3):661-674. PubMed ID: 34322779
[TBL] [Abstract][Full Text] [Related]
28. A radiosensitivity gene signature and PD-L1 status predict clinical outcome of patients with invasive breast carcinoma in The Cancer Genome Atlas (TCGA) dataset.
Jang BS; Kim IA
Radiother Oncol; 2017 Sep; 124(3):403-410. PubMed ID: 28579282
[TBL] [Abstract][Full Text] [Related]
29. Prognostic role of programmed death-ligand 1 expression in patients with biliary tract cancer: a meta-analysis.
Lei C; Peng X; Gong X; Fan Y; Wu S; Liu N; Li L; Huang J; Zheng G; Long Z
Aging (Albany NY); 2019 Dec; 11(24):12568-12580. PubMed ID: 31881008
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
[TBL] [Abstract][Full Text] [Related]
31. Biphasic prognostic significance of PD-L1 expression status in patients with early- and locally advanced-stage non-small cell lung cancer.
Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
Cancer Immunol Immunother; 2021 Apr; 70(4):1063-1074. PubMed ID: 33113005
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy.
Aydin AM; Baydar DE; Hazir B; Babaoglu B; Bilen CY
World J Urol; 2020 Oct; 38(10):2537-2545. PubMed ID: 31900581
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of PD-L1 expression is associated with EMAST, density of peritumoral T-cells and recurrence-free survival in operable non-metastatic colorectal cancer.
Watson MM; Lea D; Gudlaugsson E; Skaland I; Hagland HR; Søreide K
Cancer Immunol Immunother; 2020 Aug; 69(8):1627-1637. PubMed ID: 32314040
[TBL] [Abstract][Full Text] [Related]
34. Association between CD8 and PD-L1 expression and outcomes after radical prostatectomy for localized prostate cancer.
Vicier C; Ravi P; Kwak L; Werner L; Huang Y; Evan C; Loda M; Hamid AA; Sweeney CJ
Prostate; 2021 Jan; 81(1):50-57. PubMed ID: 32986884
[TBL] [Abstract][Full Text] [Related]
35. Dynamic changes in PD-L1 expression and CD8
Choe EA; Cha YJ; Kim JH; Pyo KH; Hong MH; Park SY; Shim HS; Jung I; Lee CY; Cho BC; Kim HR
Lung Cancer; 2019 Oct; 136():30-36. PubMed ID: 31421259
[TBL] [Abstract][Full Text] [Related]
36. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
[TBL] [Abstract][Full Text] [Related]
37. A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer.
Flores-Martín JF; Perea F; Exposito-Ruiz M; Carretero FJ; Rodriguez T; Villamediana M; Ruiz-Cabello F; Garrido F; Cózar-Olmo JM; Aptsiauri N
Ann Surg Oncol; 2019 Aug; 26(8):2631-2639. PubMed ID: 31011905
[TBL] [Abstract][Full Text] [Related]
38. Development and Validation of an Immune-Based Prognostic Risk Score for Patients With Resected Non-Small Cell Lung Cancer.
He L; Huang Y; Chen X; Huang X; Wang H; Zhang Y; Liang C; Li Z; Yan L; Liu Z
Front Immunol; 2022; 13():835630. PubMed ID: 35401554
[TBL] [Abstract][Full Text] [Related]
39. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
[TBL] [Abstract][Full Text] [Related]
40. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy.
Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
Int J Clin Oncol; 2016 Oct; 21(5):946-952. PubMed ID: 26919982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
